Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.
Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, Switzerland. TBRieder@tbrieder.org.
Hans L
HL
Rieder
Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Armand
A
Van Deun
D000995:Antitubercular Agents; D006801:Humans; D007538:Isoniazid; D009169:Mycobacterium tuberculosis; D012293:Rifampin; D018088:Tuberculosis, Multidrug-Resistant
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin